<DOC>
	<DOC>NCT00604656</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this trial is to investigate the safety and efficacy of insulin aspart produced by current process compared to that of insulin aspart produced by NN2000 process in subjects with type 2 diabetes.</brief_summary>
	<brief_title>Comparison of Insulin Aspart Produced by the NN2000 Process to the Current Process in Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<criteria>Subjects with type 1 diabetes Duration of diabetes for at least 12 months Treatment with insulin aspart for at least 3 months before trial start Body Mass Index (BMI) below 35.0 kg/m2 HbA1c below 12.0% Total insulin dosage more than 1.4 IU/kg/day Recurrent major hypoglycaemia that may interfere with trial participation (as judged by the investigator) Known hypoglycaemia unawareness as judged by the investigator Known hypersensitivity or allergy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>